- Home
- REPX vs SION Comparison
REPX vs SION Comparison
Compare REPX & SION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPX
- SION
- Stock Information
- Founded
- REPX 2016
- SION 2019
- Country
- REPX United States
- SION United States
- Employees
- REPX N/A
- SION N/A
- Industry
- REPX Oil & Gas Production
- SION
- Sector
- REPX Energy
- SION
- Exchange
- REPX Nasdaq
- SION NYSE
- Market Cap
- REPX 574.1M
- SION 564.4M
- IPO Year
- REPX N/A
- SION 2025
- Fundamental
- Price
- REPX $27.19
- SION $20.87
- Analyst Decision
- REPX Strong Buy
- SION Strong Buy
- Analyst Count
- REPX 1
- SION 1
- Target Price
- REPX $47.00
- SION $32.00
- AVG Volume (30 Days)
- REPX 114.3K
- SION 265.0K
- Earning Date
- REPX 08-06-2025
- SION 08-25-2025
- Dividend Yield
- REPX 5.63%
- SION N/A
- EPS Growth
- REPX N/A
- SION N/A
- EPS
- REPX 4.67
- SION N/A
- Revenue
- REPX $412,894,000.00
- SION N/A
- Revenue This Year
- REPX $2.85
- SION N/A
- Revenue Next Year
- REPX $4.05
- SION N/A
- P/E Ratio
- REPX $5.78
- SION N/A
- Revenue Growth
- REPX 1.25
- SION N/A
- 52 Week Low
- REPX $21.98
- SION $7.26
- 52 Week High
- REPX $37.55
- SION $25.19
- Technical
- Relative Strength Index (RSI)
- REPX 51.42
- SION N/A
- Support Level
- REPX $25.89
- SION N/A
- Resistance Level
- REPX $27.32
- SION N/A
- Average True Range (ATR)
- REPX 0.99
- SION 0.00
- MACD
- REPX -0.12
- SION 0.00
- Stochastic Oscillator
- REPX 38.81
- SION 0.00
About REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations are in Kansas Properties and Tennessee Properties, among others.
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.